Stock Ratings / Health Care / ACTU / financials

KYNB (32) AKTX (37) MCRB (40) COCP (36) ⌘ Pro Terminal →

Actuate Therapeutics Inc. (ACTU) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.34 -9.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.33

Actuate Therapeutics Inc. (ACTU) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $18.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACTU Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (-9.68% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACTU ranks #610 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACTU compare to KYNB and AKTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACTU?

▼

Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $0 in revenue, -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.33 (-1.93%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACTU)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY ACTU SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.47+31.9% Next Q

Q2 (-2Q)

Grade D$0.62-35.5% Next Q

Q3 (-1Q)

Grade E$0.40-15% Next Q

Current

Grade D-$0.34-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACTU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACTU currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.36) forces dealer call-delta covering toward $8.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACTU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACTU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ACTU Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.6%	-$22.2M	-$19.2M	-45%
FY 2024	$4.00B	52%	-0.6%	-$27.3M	-$21.8M	-45%
FY 2023	$4.00B	52%	-0.6%	-$24.7M	-$21.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACTU)

✓Walkthrough of ACTU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACTU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.47%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.38H $0.38L $0.34C $0.34VOL 489.5K

RES: $1.04SUP: $0.26SMA50: $0.87SMA200: $2.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACTU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACTU Butterfly Map → + Track ACTU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACTU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACTU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACTU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACTU)

Health Care Rank #610 of 1016 ⚔️ KYNB vs ACTU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACTU vs. KYNB, AKTX, MCRB, COCP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Actuate Therapeutics Inc. (ACTU) ranks #610 by composite RQD confidence (35/100, grade D-) and #836 by equity capitalization ($18.4M). Within this direct 5-issuer industry benchmark cohort, ACTU leads on earnings valuation at N/A trailing P/E, while ACTU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ACTU at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACTU ACTIVE Actuate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.68%	$18.4M	Benchmark Subject
KYNB Kyntra Bio Inc.	E	32/100	—	91.4%	-35.0%	-1.72%	$18.5M	/kynb-vs-actu →
AKTX Akari Therapeutics plc ADS	D-	37/100	—	—	-35.0%	+3.00%	$18.8M	/aktx-vs-actu →
MCRB Seres Therapeutics Inc.	D-	40/100	—	—	-35.0%	-9.23%	$17.8M	/mcrb-vs-actu →
COCP Cocrystal Pharma Inc.	D-	36/100	—	—	-35.0%	+1.53%	$19.2M	/cocp-vs-actu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001652935

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$22.2M, operating cash flow of -$19.2M, and free cash flow of -$19.2M (+12.1% YoY). On the balance sheet, ACTU closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$22.2M	-$19.2M	-$19.2M	$14.0M	—
FY2024 (FY)	2024-12-31	$0	-$27.3M	-$21.8M	-$21.8M	$9.3M	—
FY2023 (FY)	2023-12-31	$0	-$24.7M	-$21.6M	-$21.6M	—	—

3. ACTU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ACTU compare to KYNB and AKTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ACTU?

Where is ACTU trading relative to its 50-day, 200-day, and 52-week technical levels?

ACTU last traded at $0.34 (-9.68% on volume of 489,506 shares), positioning the stock -60.92% below its 50-day simple moving average ($0.87) and -83.89% below its 200-day simple moving average ($2.11). Across its 52-week range of $0.33 to $7.90, ACTU sits at the 0.1% percentile with a 14-day RSI of 33.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.38).

ACTU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Actuate Therapeutics Inc. (ACTU)?

In FY 2025 (10-K), ACTU converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ACTU RQD Cockpit ACTU 12M Forecast ACTU Earnings & Move ACTU Dividends & DRIP ACTU Insiders & 13F ACTU Whale Options ACTU Profit Sankey ACTU News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ACTU — Actuate Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ACTU scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 6 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow.
Whale 13F Flow: 5 / 20. The rating reflects institutional accumulation and options positioning. The holders section contains no data, so this score cannot be traced to specific filings in this source set.
Insider Conviction: 5 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. No insider transaction detail is available in this source set beyond the news headline referencing a Form 4 filing.
Macro Regime Fit: 9 / 20. The rating cites a beta of 1.0 and sector sensitivity. This indicates market-level sensitivity without a standalone demand driver evident in the data.
Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. The Piotroski score is weak, and the Altman figure sits in a zone that warrants caution.

Taken together, the pillar scores point to weak cash generation and a balance sheet that the rating treats as vulnerable. A prospective investor evaluating the stock today would weigh the sharp price decline (52-week range $0.33 to $7.9) against the ongoing cash burn reflected in the financials. Upside would depend on the company converting its financing activity into sustained operating progress, which the source data does not demonstrate. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are unavailable in the source data.

Business

Actuate Therapeutics Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe specific products, customers, or revenue streams. The FY 2025 and FY 2024 revenue figures are reported as $0.0M, and the company's model of monetization is not detailed in the sources.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-22.5M	$-22.2M	N/A	$-19.2M	$13.2M	N/A
FY 2024	$0.0M	$-25.2M	$-27.3M	N/A	$-21.8M	$8.6M	N/A
FY 2023	$0.0M	$-25.0M	$-24.7M	N/A	$-21.6M	N/A	N/A

Per the SEC financials, the company reported no revenue across the three periods and operating losses in each year. Net margin, gross margin, and operating margin are each listed as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with a Debt/Equity ratio of 0.5. Cash rose from $8.6M in FY 2024 to $13.2M in FY 2025 while free cash flow remained negative, and the source data does not reconcile how that cash increase was funded.

Recent Catalysts & News Wire Analysis

The news feed contains six items, all tagged to ACTU:

A Yahoo! Finance Canada report on market action and institutional positioning (YELLOW).
A Moomoo report on market action and analyst ratings (YELLOW).
A Quantisnow report referencing a SEC Form 4 filing by the company (YELLOW).
A WBOC TV report announcing pricing of an $11.0 Million underwritten public offering (YELLOW).
A Stock Titan report referencing a proposed stock offering at an assumed $0.819 per share (YELLOW).
A TradingView report on a $9.96 Million stock-and-warrant offering (GREEN, tagged CATALYST).

The most material items are the financing announcements. Per the news wire, the company priced an $11.0 Million underwritten public offering and separately raised $9.96 Million through a stock-and-warrant offering. These financings are consistent with the cash figure of $13.2M in FY 2025 and the continued negative free cash flow. The Butterfly supply-chain graph reports no proprietary signals, so there are no additional signal-based catalysts in the source data. The risk watch item is dilution: the offering price referenced as assumed at $0.819 per share compares with the current price of 0.37 in the market data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be identified from the source data. Sector correlations are likewise not available beyond the classification of Health Care and Biotechnology: Pharmaceutical Preparations. A prospective investor should note that the absence of mapped links means second-order bottlenecks cannot be assessed here, and any ripple analysis would require information outside this source set.

Open Questions

What products or pipeline assets generate the company's business case, and what regulatory milestones are attached to them? The sources do not describe this.
How were the FY 2025 cash balance of $13.2M and the recent offerings structured, and what is the company's runway at the FY 2025 burn rate of $-19.2M in free cash flow?
What is the debt composition behind the reported Debt/Equity ratio of 0.5, given that the debt line is listed as N/A in every period?
What were the terms, dilution impact, and warrant exercise prices of the $11.0 Million offering and the $9.96 Million stock-and-warrant raise?
What drove the 52-week price decline from $7.9 to $0.33, and does the company retain its listing standing at the current price of 0.37?

ACTU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Actuate Therapeutics Inc. (ACTU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACTU Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago

Actuate Therapeutics, Inc. Common stock (ACTU) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 21h ago

Actuate Therapeutics (ACTU) Stock Forecast & Analyst Ratings

Moomoo report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quantisnow • 1d ago

SEC Form 4 filed by Actuate Therapeutics Inc.

Quantisnow report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE WBOC TV • 1d ago

Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

WBOC TV report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering.

Stock Titan report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Actuate Therapeutics Raises $9.96 Million in Stock-and-Warrant Offering

TradingView report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Actuate Therapeutics CEO Daniel Schmitt purchases $49,999 in stock

Investing.com report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Actuate Therapeutics (ACTU) Secures USPTO Notice of Allowance fo

GuruFocus report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACTU Bull vs. Bear Conversation Board — What's Your Call at $0.34?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACTU 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.33 (-10.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ACTU (D- • RQD 35/100) a Buy at $0.37?

Welcome to the ACTU (Actuate Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.30 (-18.9%)

Spot @ $0.37

Pump the brakes on ACTU — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ACTU, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Actuate Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.43 (+16.2%)

Spot @ $0.37

ACTU cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ACTU, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.37 (52-wk range $0.33 - $7.90), any beat on forward guidance forces shorts and underweight funds to chase.